Blair William & CO Argenx Se Transaction History

Blair William & CO

$32 Billion
Q2 2024

A detailed history of Blair William & CO transactions in Argenx Se stock. As of the latest transaction made, Blair William & CO holds 911 shares of ARGX stock, worth $490,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares

911

Previous 1,445 36.96%

Holding current value

$490,537

Previous $568,000 31.16%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$356.01 - $451.55 $190,109 - $241,127	-534 Reduced 36.96%	911 $391,000
Q1 2024 May 09, 2024	SELL	$356.95 - $413.29 $248,080 - $287,236	-695 Reduced 32.48%	1,445 $568,000
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $88,455 - $132,068	261 Added 13.89%	2,140 $814,000
Q3 2023 Nov 09, 2023	BUY	$369.35 - $548.43 $58,726 - $87,200	159 Added 9.24%	1,879 $923,000
Q2 2023 Aug 11, 2023	BUY	$360.14 - $422.58 $243,094 - $285,241	675 Added 64.59%	1,720 $670,000
Q1 2023 May 12, 2023	SELL	$334.23 - $403.65 $125,336 - $151,368	-375 Reduced 26.41%	1,045 $389,000
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $54,062 - $63,564	-158 Reduced 10.01%	1,420 $537,000
Q3 2022 Nov 09, 2022	BUY	$343.2 - $395.75 $1,029 - $1,187	3 Added 0.19%	1,578 $557,000
Q1 2022 May 13, 2022	SELL	$254.45 - $351.06 $3,053 - $4,212	-12 Reduced 0.76%	1,575 $497,000
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $3,264 - $4,236	12 Added 0.76%	1,587 $556,000
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $167,879 - $258,630	1,575 New	1,575 $253,000
Q3 2019 Nov 12, 2019	SELL	$113.31 - $150.51 $249,282 - $331,122	-2,200 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$98.85 - $134.59 $217,470 - $296,098	2,200 New	2,200 $275,000

Others Institutions Holding ARGX

# of Institutions

371

Shares Held

31.4M

Call Options Held

303K

Put Options Held

429K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $29.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account